Drugs / Piamprizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04897477 | Apr 2021 → Apr 2022 | B-cell non-Hodgkin lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Piamprizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04897477 ↗ |
| Route | Intravenous | “Bendamustine and Piamprizumab intravenous infusion” NCT04897477 ↗ |